BidaskClub upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN) from a strong sell rating to a sell rating in a report issued on Tuesday morning, BidAskClub reports.

A number of other analysts also recently issued reports on the company. JPMorgan Chase & Co. reaffirmed a buy rating on shares of BioMarin Pharmaceutical in a research report on Sunday, June 2nd. Wedbush reaffirmed a buy rating and issued a $128.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, May 28th. Citigroup reaffirmed a buy rating on shares of BioMarin Pharmaceutical in a research report on Thursday, May 23rd. TheStreet downgraded BioMarin Pharmaceutical from a c- rating to a d+ rating in a research report on Tuesday, May 7th. Finally, Robert W. Baird set a $120.00 target price on BioMarin Pharmaceutical and gave the company a buy rating in a research report on Friday, April 26th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $116.00.

BMRN opened at $81.09 on Tuesday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.76 and a current ratio of 3.83. The stock has a market capitalization of $14.52 billion, a price-to-earnings ratio of -245.73 and a beta of 1.40. BioMarin Pharmaceutical has a 1 year low of $79.13 and a 1 year high of $106.74.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, April 25th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. The business had revenue of $400.70 million for the quarter, compared to the consensus estimate of $389.95 million. BioMarin Pharmaceutical had a negative return on equity of 2.97% and a negative net margin of 5.90%. BioMarin Pharmaceutical’s quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.12 earnings per share. On average, analysts expect that BioMarin Pharmaceutical will post -0.04 EPS for the current fiscal year.

In other BioMarin Pharmaceutical news, SVP Brian Mueller sold 2,953 shares of the business’s stock in a transaction that occurred on Friday, April 5th. The stock was sold at an average price of $94.00, for a total transaction of $277,582.00. Following the transaction, the senior vice president now owns 13,660 shares of the company’s stock, valued at $1,284,040. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Jean Jacques Bienaime sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $94.40, for a total value of $377,600.00. Following the transaction, the chief executive officer now directly owns 300,558 shares in the company, valued at approximately $28,372,675.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 80,815 shares of company stock worth $7,195,608. Company insiders own 1.97% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Slow Capital Inc. lifted its stake in BioMarin Pharmaceutical by 2.4% during the first quarter. Slow Capital Inc. now owns 7,148 shares of the biotechnology company’s stock worth $635,000 after purchasing an additional 170 shares during the last quarter. Aristeia Capital LLC bought a new stake in BioMarin Pharmaceutical during the first quarter worth $3,447,000. Covenant Partners LLC bought a new stake in BioMarin Pharmaceutical during the first quarter worth $274,000. CWM Advisors LLC lifted its stake in BioMarin Pharmaceutical by 70.6% during the first quarter. CWM Advisors LLC now owns 5,049 shares of the biotechnology company’s stock worth $449,000 after purchasing an additional 2,089 shares during the last quarter. Finally, RMB Capital Management LLC lifted its stake in BioMarin Pharmaceutical by 4.2% during the first quarter. RMB Capital Management LLC now owns 3,697 shares of the biotechnology company’s stock worth $328,000 after purchasing an additional 148 shares during the last quarter. 98.54% of the stock is currently owned by hedge funds and other institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Recommended Story: How do candlesticks reflect price movement?

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.